Expanded access policy

Spyre Therapeutics, Inc. is committed to discovering and developing next generation therapeutics for people living with inflammatory conditions, including ulcerative colitis (UC), Crohn’s disease (CD), and rheumatologic disease (RD). Our goal is to conduct our clinical trials efficiently in order to obtain marketing authorization for our therapeutic candidates from the U.S. Food and Drug Administration (FDA) and other regulatory agencies to ensure wider patient access.

Currently, access to our investigational therapeutic candidates is not available via Expanded Access. We encourage all patients who may be eligible for one of our clinical trials to speak with their physicians about the possibility of participating in these clinical trials. Clinical trial participants support the research and development of and have the potential to obtain access to our investigational therapeutic candidates. For a list of our clinical trials and research locations, please visit www.clincialtrials.gov.

Spyre is committed to addressing the needs of patients and will re-evaluate the status of this policy periodically and may revise it at any time.

In the U.S., physicians may find additional information regarding Expanded Access to investigational therapies by visiting https://www.fda.gov/newsevents/expanded-access/expanded-access-information-physicians.